David MD - Roivant Sciences Chief Dermavant
| ROIV Stock | USD 12.15 0.05 0.41% |
Executive
David MD is Chief Dermavant of Roivant Sciences
| Address | 50 Broadway, London, United Kingdom, SW1H 0DB |
| Phone | 44 20 7400 3347 |
| Web | https://roivant.com |
Roivant Sciences Management Efficiency
The company has return on total asset (ROA) of (0.1844) % which means that it has lost $0.1844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.2896 %, meaning that it created $1.2896 on every $100 dollars invested by stockholders. Roivant Sciences' management efficiency ratios could be used to measure how well Roivant Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.64 in 2024. Return On Capital Employed is likely to climb to 0.64 in 2024. At this time, Roivant Sciences' Asset Turnover is fairly stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kathryn CPA | Krystal Biotech | 43 | |
| Kevin McManus | Syndax Pharmaceuticals | 55 | |
| Yang Ji | BeiGene | N/A | |
| Mike JD | Pliant Therapeutics | 51 | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| JD Esq | Phathom Pharmaceuticals | N/A | |
| Jason Radford | BeiGene | 42 | |
| John Jordan | Viridian Therapeutics | N/A | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| Yan Qi | BeiGene | N/A | |
| Eric MD | Pliant Therapeutics | 60 | |
| Julia Wang | BeiGene | 53 | |
| Jennifer JD | Viridian Therapeutics | 52 | |
| Anthony Casicano | Viridian Therapeutics | 47 | |
| Catherine MD | Syndax Pharmaceuticals | 52 | |
| Jeffrey Eisele | Apellis Pharmaceuticals | 62 | |
| Karen Lewis | Apellis Pharmaceuticals | 51 | |
| JD Esq | Apellis Pharmaceuticals | 51 | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Joseph Kelly | Ascendis Pharma AS | 55 | |
| Sharon Klahre | Syndax Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | 1.29 | ||||
| Return On Asset | -0.18 |
Roivant Sciences Leadership Team
Elected by the shareholders, the Roivant Sciences' board of directors comprises two types of representatives: Roivant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roivant. The board's role is to monitor Roivant Sciences' management team and ensure that shareholders' interests are well served. Roivant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roivant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amy Mahery, Chief Officer | ||
| Matthew Gline, CEO Director | ||
| Marianne Romeo, Head Management | ||
| Huafeng Xu, Chief Officer | ||
| Josh Chen, General Counsel | ||
| Matt Maisak, Chief Platforms | ||
| Vivek Ramaswamy, Founder Chairman | ||
| Alex Gasner, Executive Health | ||
| Jo Chen, General Counsel | ||
| PharmD MD, President COO | ||
| Drew Kramer, Chief Officer | ||
| Kelly Graff, Head People | ||
| Richard Pulik, Chief Officer | ||
| Deya MD, Chief OfficerInResidence | ||
| Srini Ramanathan, Chief Officer | ||
| Rakhi Kumar, Chief Officer | ||
| Josh JD, General Counsel | ||
| Mayukh MD, Chief President | ||
| David MD, Chief Dermavant |
Roivant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Roivant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.29 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | 37.25 % | ||||
| Operating Margin | (74.46) % | ||||
| Current Valuation | 3.51 B | ||||
| Shares Outstanding | 727.95 M | ||||
| Shares Owned By Insiders | 28.92 % | ||||
| Shares Owned By Institutions | 79.48 % | ||||
| Number Of Shares Shorted | 47.81 M | ||||
| Price To Book | 1.72 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.